Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Endometrium | | AEH: Atypical endometrial hyperplasia |
EEC: Endometrioid Cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00614582 | Colorectum | MSS | reproductive system development | 115/3467 | 427/18723 | 9.86e-06 | 2.39e-04 | 115 |
GO:00486082 | Colorectum | MSS | reproductive structure development | 113/3467 | 424/18723 | 1.94e-05 | 4.18e-04 | 113 |
GO:00467182 | Colorectum | MSS | viral entry into host cell | 47/3467 | 144/18723 | 3.35e-05 | 6.56e-04 | 47 |
GO:00444092 | Colorectum | MSS | entry into host | 47/3467 | 151/18723 | 1.24e-04 | 1.91e-03 | 47 |
GO:00065751 | Colorectum | MSS | cellular modified amino acid metabolic process | 55/3467 | 188/18723 | 2.16e-04 | 3.01e-03 | 55 |
GO:0001893 | Colorectum | MSS | maternal placenta development | 13/3467 | 35/18723 | 7.38e-03 | 4.68e-02 | 13 |
GO:00160323 | Colorectum | MSI-H | viral process | 74/1319 | 415/18723 | 8.87e-14 | 2.05e-11 | 74 |
GO:00190583 | Colorectum | MSI-H | viral life cycle | 53/1319 | 317/18723 | 3.27e-09 | 4.32e-07 | 53 |
GO:00444033 | Colorectum | MSI-H | biological process involved in symbiotic interaction | 41/1319 | 290/18723 | 1.53e-05 | 6.62e-04 | 41 |
GO:00517013 | Colorectum | MSI-H | biological process involved in interaction with host | 28/1319 | 203/18723 | 4.88e-04 | 1.02e-02 | 28 |
GO:00521263 | Colorectum | MSI-H | movement in host environment | 24/1319 | 175/18723 | 1.29e-03 | 2.04e-02 | 24 |
GO:00065752 | Colorectum | MSI-H | cellular modified amino acid metabolic process | 25/1319 | 188/18723 | 1.61e-03 | 2.39e-02 | 25 |
GO:00467183 | Colorectum | MSI-H | viral entry into host cell | 20/1319 | 144/18723 | 2.70e-03 | 3.50e-02 | 20 |
GO:00160324 | Colorectum | FAP | viral process | 114/2622 | 415/18723 | 3.00e-13 | 2.63e-10 | 114 |
GO:00190584 | Colorectum | FAP | viral life cycle | 81/2622 | 317/18723 | 2.97e-08 | 2.64e-06 | 81 |
GO:00444034 | Colorectum | FAP | biological process involved in symbiotic interaction | 66/2622 | 290/18723 | 3.47e-05 | 7.64e-04 | 66 |
GO:00018903 | Colorectum | FAP | placenta development | 38/2622 | 144/18723 | 6.22e-05 | 1.21e-03 | 38 |
GO:00521264 | Colorectum | FAP | movement in host environment | 42/2622 | 175/18723 | 2.64e-04 | 3.60e-03 | 42 |
GO:00517014 | Colorectum | FAP | biological process involved in interaction with host | 47/2622 | 203/18723 | 2.89e-04 | 3.77e-03 | 47 |
GO:00614583 | Colorectum | FAP | reproductive system development | 85/2622 | 427/18723 | 4.30e-04 | 5.13e-03 | 85 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0461218 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa042108 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
hsa0461219 | Breast | Precancer | Antigen processing and presentation | 19/684 | 78/8465 | 9.61e-06 | 1.12e-04 | 8.62e-05 | 19 |
hsa0421013 | Breast | Precancer | Apoptosis | 25/684 | 136/8465 | 7.61e-05 | 6.87e-04 | 5.26e-04 | 25 |
hsa0461223 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0421022 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
hsa0461233 | Breast | IDC | Antigen processing and presentation | 24/867 | 78/8465 | 4.61e-07 | 8.33e-06 | 6.23e-06 | 24 |
hsa0421032 | Breast | IDC | Apoptosis | 31/867 | 136/8465 | 1.34e-05 | 1.61e-04 | 1.20e-04 | 31 |
hsa0461242 | Breast | DCIS | Antigen processing and presentation | 25/846 | 78/8465 | 6.75e-08 | 1.28e-06 | 9.45e-07 | 25 |
hsa0421041 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
hsa0461252 | Breast | DCIS | Antigen processing and presentation | 25/846 | 78/8465 | 6.75e-08 | 1.28e-06 | 9.45e-07 | 25 |
hsa0421051 | Breast | DCIS | Apoptosis | 29/846 | 136/8465 | 5.92e-05 | 5.97e-04 | 4.40e-04 | 29 |
hsa0461220 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa042109 | Cervix | CC | Apoptosis | 36/1267 | 136/8465 | 3.21e-04 | 1.68e-03 | 9.91e-04 | 36 |
hsa046213 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa04612110 | Cervix | CC | Antigen processing and presentation | 34/1267 | 78/8465 | 1.06e-09 | 2.14e-08 | 1.26e-08 | 34 |
hsa0421014 | Cervix | CC | Apoptosis | 36/1267 | 136/8465 | 3.21e-04 | 1.68e-03 | 9.91e-04 | 36 |
hsa0462112 | Cervix | CC | NOD-like receptor signaling pathway | 41/1267 | 186/8465 | 5.90e-03 | 1.95e-02 | 1.15e-02 | 41 |
hsa0421023 | Cervix | HSIL_HPV | Apoptosis | 16/459 | 136/8465 | 2.74e-03 | 1.78e-02 | 1.44e-02 | 16 |
hsa0421033 | Cervix | HSIL_HPV | Apoptosis | 16/459 | 136/8465 | 2.74e-03 | 1.78e-02 | 1.44e-02 | 16 |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | Dimethoxybenzylidene-2-thio-imidazole-4-one derivative 1 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 178103148 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | PMID27998201-Compound-22 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | PMID27998201-Compound-9 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | PMID27998201-Compound-12 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | PMID27998201-Compound-11 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | PMID27998201-Compound-5 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 405067337 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | inhibitor | 405560408 | | |
1508 | CTSB | DRUGGABLE GENOME, PROTEASE, EXTERNAL SIDE OF PLASMA MEMBRANE, ENZYME | | PMID27998201-Compound-17 | | |